Protagonist Therapeutics, Inc.
PTGX
$155.10
$3.682.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 281.99M | 74.06M | 46.02M | 209.22M | 209.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 281.99M | 74.06M | 46.02M | 209.22M | 209.18M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 281.99M | 74.06M | 46.02M | 209.22M | 209.18M |
| SG&A Expenses | 48.49M | 46.39M | 44.85M | 42.37M | 41.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 223.65M | 216.53M | 204.14M | 190.21M | 185.20M |
| Operating Income | 58.34M | -142.47M | -158.13M | 19.01M | 23.98M |
| Income Before Tax | 84.34M | -115.38M | -129.31M | 48.07M | 53.78M |
| Income Tax Expenses | 1.43M | -664.00K | 838.00K | 2.16M | 1.74M |
| Earnings from Continuing Operations | 82.91 | -114.71 | -130.15 | 45.91 | 52.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 82.91M | -114.71M | -130.15M | 45.91M | 52.04M |
| EBIT | 58.34M | -142.47M | -158.13M | 19.01M | 23.98M |
| EBITDA | 59.88M | -141.02M | -156.85M | 20.03M | 24.87M |
| EPS Basic | 1.22 | -1.80 | -2.04 | 0.76 | 0.84 |
| Normalized Basic EPS | 0.77 | -1.13 | -1.27 | 0.50 | 0.54 |
| EPS Diluted | 1.02 | -1.82 | -2.06 | 0.63 | 0.71 |
| Normalized Diluted EPS | 0.66 | -1.13 | -1.27 | 0.42 | 0.46 |
| Average Basic Shares Outstanding | 258.83M | 256.40M | 254.28M | 252.58M | 250.57M |
| Average Diluted Shares Outstanding | 269.30M | 261.81M | 254.28M | 256.65M | 254.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |